📣 VC round data is live. Check it out!
- Public Comps
- TELA Bio
TELA Bio Valuation Multiples
Discover revenue and EBITDA valuation multiples for TELA Bio and similar public comparables like Luna Innovations, RenovoRx, Myomo, Mauna Kea Technologies and more.
TELA Bio Overview
About TELA Bio
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. Its growing product portfolio is purposefully designed to leverage the patient’s natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
Founded
2012
HQ

Employees
209
Website
Financials (LTM)
EV
$57M
Valuation Multiples
Start free trialTELA Bio Financials
TELA Bio reported last 12-month revenue of $83M and negative EBITDA of ($30M).
In the same LTM period, TELA Bio generated $56M in gross profit, ($30M) in EBITDA losses, and had net loss of ($39M).
Revenue (LTM)
TELA Bio P&L
In the most recent fiscal year, TELA Bio reported revenue of $80M and EBITDA of ($31M).
TELA Bio is unprofitable as of last fiscal year, with gross margin of 68%, EBITDA margin of (38%), and net margin of (48%).
Financial data powered by Morningstar, Inc.
TELA Bio Stock Performance
TELA Bio has current market cap of $40M, and enterprise value of $57M.
Market Cap Evolution
TELA Bio's stock price is $0.89.
TELA Bio share price increased by 1.9% in the last 30 days, and decreased by 35.8% in the last year.
TELA Bio has an EPS (earnings per share) of $-0.87.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $57M | $40M | 0.0% | 1.9% | 2.8% | -35.8% | $-0.87 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTELA Bio Valuation Multiples
TELA Bio trades at 0.7x EV/Revenue multiple, and (1.9x) EV/EBITDA.
EV / Revenue (LTM)
TELA Bio Financial Valuation Multiples
As of May 26, 2026, TELA Bio has market cap of $40M and EV of $57M.
TELA Bio has a P/E ratio of (1.0x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified TELA Bio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


TELA Bio Margins & Growth Rates
TELA Bio grew revenue by 8% but EBITDA decreased by 7% in the last fiscal year.
In the most recent fiscal year, TELA Bio reported gross margin of 68%, EBITDA margin of (38%), and net margin of (48%).
TELA Bio Margins
TELA Bio Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
TELA Bio Operational KPIs
TELA Bio's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.4M for the same period.
TELA Bio's Rule of 40 is (25%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
TELA Bio's Rule of X is (13%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
TELA Bio Competitors
TELA Bio competitors include Luna Innovations, RenovoRx, Myomo, Mauna Kea Technologies, Abingdon Health, Biohit, Ortoma, Theraclion, Diagnostic Medical Systems and Optomed.
Most TELA Bio public comparables operate across Medical Devices, HealthTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| — | — | — | — | |||
| 24.6x | 14.1x | (2.2x) | — | |||
| 1.1x | 1.0x | (3.8x) | (4.1x) | |||
| 5.1x | 5.2x | 3.3x | (13.5x) | |||
| 3.1x | 2.2x | (10.3x) | (22.8x) | |||
| 2.0x | — | 9.6x | — | |||
| 5.1x | 4.9x | (78.0x) | (26.7x) | |||
| 43.9x | — | (6.2x) | — | |||
This data is available for Pro users. Sign up to see all TELA Bio competitors and their valuation data. Start Free Trial | ||||||
TELA Bio Funding History
Before going public, TELA Bio raised $87M in total equity funding, across 7 rounds.
TELA Bio Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout TELA Bio
| When was TELA Bio founded? | TELA Bio was founded in 2012. |
| Where is TELA Bio headquartered? | TELA Bio is headquartered in United States. |
| How many employees does TELA Bio have? | As of today, TELA Bio has over 209 employees. |
| Who is the CEO of TELA Bio? | TELA Bio's CEO is Anthony Koblish. |
| Is TELA Bio publicly listed? | Yes, TELA Bio is a public company listed on Nasdaq. |
| What is the stock symbol of TELA Bio? | TELA Bio trades under TELA ticker. |
| When did TELA Bio go public? | TELA Bio went public in 2019. |
| Who are competitors of TELA Bio? | TELA Bio main competitors include Luna Innovations, RenovoRx, Myomo, Mauna Kea Technologies, Abingdon Health, Biohit, Ortoma, Theraclion, Diagnostic Medical Systems, Optomed. |
| What is the current market cap of TELA Bio? | TELA Bio's current market cap is $40M. |
| What is the current revenue of TELA Bio? | TELA Bio's last 12 months revenue is $83M. |
| What is the current revenue growth of TELA Bio? | TELA Bio revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of TELA Bio? | Current revenue multiple of TELA Bio is 0.7x. |
| Is TELA Bio profitable? | No, TELA Bio is not profitable. |
| What is the current EBITDA of TELA Bio? | TELA Bio has negative EBITDA and is not profitable. |
| What is TELA Bio's EBITDA margin? | TELA Bio's last 12 months EBITDA margin is (36%). |
| What is the current EV/EBITDA multiple of TELA Bio? | Current EBITDA multiple of TELA Bio is (1.9x). |
| What is the current FCF of TELA Bio? | TELA Bio's last 12 months FCF is ($32M). |
| What is TELA Bio's FCF margin? | TELA Bio's last 12 months FCF margin is (39%). |
| What is the current EV/FCF multiple of TELA Bio? | Current FCF multiple of TELA Bio is (1.7x). |
| How many companies TELA Bio has acquired to date? | TELA Bio hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies TELA Bio has invested to date? | TELA Bio hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to TELA Bio
Lists including TELA Bio
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.